1 / 1

Pre-RELAX-AHF

Pre-RELAX-AHF. Moderately or markedly improved dyspnea: 28% with 10 µg relaxin (p = 0.54 vs. placebo), 40% with 30 µg (p = 0.044), 14% with 100 µg (p = 0.28), 22% with 250 µg (p = 0.86), and 23% with placebo

daw
Download Presentation

Pre-RELAX-AHF

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pre-RELAX-AHF Moderately or markedly improved dyspnea: 28% with 10 µg relaxin (p = 0.54 vs. placebo), 40% with 30 µg (p = 0.044), 14% with 100 µg (p = 0.28), 22% with 250 µg (p = 0.86), and 23% with placebo CV death at 180 days: 2.5% (p = 0.15 vs. placebo), 0% (p = 0.046), 2.9% (p = 0.17), 6.2% (p = 0.53), and 14.3%, respectively Trial design: Patients admitted with acute HF were randomized to IV placebo (n = 62) or one of four doses of IV relaxin for 48 hours: 1) 10 µg/kg daily (n = 40), 2) 30 µg/kg daily (n = 43), 3) 100 µg/kg daily (n = 39), or 4) 250 µg/kg daily (n = 50). Results 40 28 22 23 % 14 Conclusions Patients with moderately or markedly improved dyspnea • Among patients with decompensated HF, the use of relaxin appeared to be effective in improving heart failure symptoms • Among the four doses of relaxin, the 30 µg/kg daily dose appeared to provide the most benefit in dyspnea improvement vs. placebo 100 µg 10 µg Placebo 30 µg 250 µg Teerlink JR, et al. Lancet 2009;373:1429-39

More Related